Compare Crispr Therapeutics AG (CRSP) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Intuitive Surgical, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.52 (market cap $4.97B), while Intuitive Surgical, Inc. trades at $390.79 (market cap $134.40B). The key difference: Intuitive Surgical, Inc. is far larger — about 27× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| CRSP | ISRG | |
|---|---|---|
Market Cap | $4.97B | $134.40B |
Sector | Health | Health |
52-Week High | $76.78 | $592.85 |
52-Week Low | $44.34 | $379.50 |
Enterprise Value | $3.32B | $129.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Intuitive Surgical (ISRG) trades at $407.12, showing minimal daily change. The stock is in a bearish technical trend but maintains strong fundamentals with consistent revenue growth, expanding profit margins, and a history of earnings beats. Recent news highlights near-term headwinds and a significant decline from 52-week highs, yet analyst sentiment remains largely positive, focusing on long-term robotic surgery market penetration.
The outlook balances strong fundamentals against technical weakness. Investment opportunity lies in market leadership and earnings growth potential, but risks include competitive pressures and execution challenges. Wall Street consensus is bullish with a $557.60 price target, suggesting substantial upside if the company navigates current challenges successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
